Cormorant Asset Management
200 Clarendon StreetBoston, MA 2116
Website: cormorant-asset.com
Firm Size
- Assets Under Management (AUM):$4 Billion
- Number of Funds:6
- Employees:14
- Firm Type:Private Equity
- Focus Areas:
Software & Technology
Healthcare
Description
Cormorant Asset Management, LP is a Boston-based investment management firm. The company specializes in managing alternative investments and focuses on long-term growth through a diversified portfolio. Founded by Bihua Chen in 2013, Cormorant Asset Management employs a research-driven approach that combines fundamental analysis with scientific and medical expertise. The firm primarily invests in the healthcare sector, with a specific focus on biotechnology and pharmaceutical companies. Cormorant aims to identify undervalued assets and take concentrated positions to maximize returns. With its experienced team and industry knowledge, Cormorant Asset Management has gained a reputation for its successful investments in the healthcare industry.Latest News
Powered by
May 09, 2024: Aardvark Therapeutics Announces $85 Million Oversubscribed Series C Financing
Aardvark Therapeutics, Inc. announces an $85 million oversubscribed Series C financing led by Decheng Capital, with participation from Cormorant Asset Management, Surveyor Capital, SymBiosis, Tetragon Financial Group, Walleye Capital, Laurion Capital Management, LG Technology Ventures, Cantor Fitzgerald & Co., Silver Arc Private Capital, The Prader-Willi Syndrome Association – USA , and existing investors, including Vickers Venture Partners and the Foundation for Prader-Willi Research.
May 07, 2024: Averto Medical Debuts with Oversubscribed $30M Series A Financing to Advance Innovative Medical Device that Avoids Need for Ostomy
Averto Medical Inc ("Averto", "The Company"), a clinical-stage medical device company pioneering minimally invasive gastrointestinal care, today announced the closing of an oversubscribed $30.5 million Series A financing. Cormorant Asset Management led the financing with participation from Venrock Healthcare Capital Partners, LifeSci Venture Partners, CVF, and other investors.
Jan 02, 2024: Enavate Sciences Backs Graviton Bioscience in Financing Round to Advance Development of Selective ROCK2 Inhibitors
Graviton Bioscience, a privately held clinical-stage biotechnology company focused on therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2) announced completion of financing from Enavate Sciences , a portfolio company of Patient Square Capital . Proceeds from Enavate's investment will help to advance clinical development of GV101 and Graviton's pipeline of ROCK2 inhibitors to treat a range of serious fibrotic, inflammatory and neurologic conditions.
Dec 07, 2023: Spyre Therapeutics Announces $180 Million Private Placement
Spyre Therapeutics, Inc. ("Spyre") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $180 million to the Company, before deducting placement agent fees and offering expenses. The PIPE financing included participation from both new and existing investors, including Access Biotechnology, Venrock Healthcare Capital Partners, Perceptive Advisors, RTW Investments, LP, Braidwell LP, Fairmount, Cormorant Asset Management, Polar Capital, Boxer Capital, Deep Track Capital, Great Point Partners LLC, Affinity Asset Advisors, Commodore Capital, Woodline Partners LP, a leading biotechnology investor associated with one of the largest alternative asset managers, and a large investment management firm.
Nov 21, 2023: SUPIRA MEDICAL, INC., A SHIFAMED PORTFOLIO COMPANY, RECEIVES FDA BREAKTHROUGH DEVICE DESIGNATION AS THE COMPANY CLOSED $40M IN SERIES D FINANCING
Supira Medical, Inc. , a Shifamed portfolio company, announced today that it has received U.S. Food and Drug Administration (FDA) breakthrough device designation for its Supira System, a next-generation percutaneous ventricular assist device (pVAD). This approval comes as the company closed $40M in Series D financing and prepares to initiate its U.S. clinical program. The financing was led by Cormorant Asset Management and The Capital Partnership (TCP), with participation from 415 CAPITAL, AMED Ventures, PA MedTech VC fund, Unorthodox Ventures and Shifamed angel investors. Funds will be used to expand Supira's currently enrolling OUS studies, plan for its U.S. studies, and prepare for U.S. pivotal study submission.
Oct 26, 2023: Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders
Triveni Bio Inc., a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders, today announced a $92 million series A financing co-led by Atlas Venture and Cormorant Asset Management, with participation from OrbiMed, the private equity business of Viking Global Investors, Invus, Polaris Partners, Alexandria Venture Investments, and other investors.
Oct 03, 2023: Akura Medical, a Shifamed Portfolio Company, Closes $35M in Series B Financing
Akura Medical , a Shifamed portfolio company focused on a differentiated approach to effectively address the major challenges of venous thromboembolism (VTE), announced today the closing of its $35M Series B financing. The funds will be used to apply for FDA 510(k) clearance for the Akura Mechanical Thrombectomy Platform, support clinical trials for additional indications, and scale manufacturing capabilities. The financing was led by The Capital Partnership (TCP) and Cormorant Asset Management, with significant participation from the PA MedTech VC Fund, AMED Ventures, Lilly Asia Ventures, Unorthodox Ventures and Shifamed angel investors.
Jun 26, 2023: MYRA VISION, A SHIFAMED PORTFOLIO COMPANY, CLOSES $25M IN SERIES B FINANCING
Myra Vision , a Shifamed portfolio company, announced today the closing of its $25M Series B financing. Led by Cormorant Asset Management, with significant participation from The Capital Partnership (TCP), the PA MedTech VC Fund and Shifamed angel investors, the funds will be used to further product development, scale manufacturing capabilities, and support first-in-human investigation of the company's Calibreye ™ System, a novel treatment that aims to optimize reduction of intraocular pressure (IOP) for patients with moderate to advanced glaucoma.
Apr 13, 2023: BioVentrix® Closes $48.5 Million Series A Financing
BioVentrix, Inc ., a privately held medical device company developing minimally invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process in patients with congestive heart failure, today announced the completion of $48.5 million Series A round financing.